Medartis raised a total of CHF 142.6MM, including an over-allotment of shares, in its IPO. Funds will support the company's strategic growth initiatives.
Study results demonstrated that improvements in pain and function from use of Vericel's MACI vs. microfracture in the treatment of knee cartilage defects were sustained for five years following surgery.